Expression of XXXX , @entity540 , phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell @entity2 .

@entity1 @entity8736 @entity5 @entity957 @entity1149 @entity2 @entity3794 @entity13344 @entity540 @entity1442 @entity10412 @entity74 @entity378 @entity204 @entity7167
AIM: @entity1149 is the leading cause of @entity5 related to @entity204 in the world. @entity957 ( @entity957 ) is the second most frequent histological @entity2 . Recently, growth factors, growth factor receptors, and signal transduction system-related gene amplifications and mutations are extensively under investigation to estimate the prognosis and to develop individualized therapies in @entity957 . In this study, besides the signal transduction molecule @entity8736 kinase ( @entity13344 ) p110a, we explored the expressions of @entity540 ( @entity540 ) and receptor-1 ( @entity7167 ) in @entity5 tissue and also their clinical and prognostic significance in @entity1 with early/advanced @entity957 . MATERIALS AND METHODS: From 2005 to 2013, 129 @entity1 (23 early, 106 @entity1442 ) with a histopathological @entity957 diagnosis were selected from the hospital files of Cukurova University Medical Faculty for this study. Two independent pathologists evaluated @entity7167 , @entity540 , and @entity10412 (p110a) expressions in both @entity5 and stromal tissues from 99 of the @entity1 with sufficient tissue samples, using immunohistochemistry. Considering survival analysis separately for @entity1 with both early and advanced stage diseases, the relationship between the clinical features of the @entity1 and expressions were evaluated by univariate and multivariate analyses. RESULTS: @entity7167 expression was found to be low in 59 (60%) @entity1 and high in 40 (40%) @entity1 . For @entity540 ; 12 (12%) @entity1 had high, 87 (88%) @entity1 had low expression and for @entity13344 ; 31 (32%) @entity1 had high and 66 (68%) @entity1 had low expressions. In univariate analysis, overall survival (OS) was significantly associated with stage of the disease and the performance status of the @entity1 (P<0.0001 and P<0.001). There was no significant difference in OS of the @entity1 with either low or high expressions of @entity7167 , @entity540 , and @entity13344 . When the @entity1 with early or advanced stage disease were separately taken into consideration, the relationship did not differ, either. Any of @entity7167 , @entity540 or @entity13344 expressions was not found predictive for the treatment of early or advanced staged @entity1 . On the other hand, the expressions of both @entity7167 and @entity540 were significantly different with respect to smoking, scar of @entity378 and scar of radiotherapy (P=0.002; P=0.06 and P=0.05, respectively). DISCUSSION: There has not been identified an effective individualized treatment for @entity957 yet. Therefore, in order to be able to develop such a treatment in the future, it is essential to identify the @entity74 that are responsible for the biological behaviors and carcinogenesis of @entity957 . Although we could not show the prognostic and predictive significance of @entity7167 , @entity540 and @entity13344 expressions in @entity957 , we determined the expression rates of @entity7167 , @entity540 and @entity13344 as a reference for Turkish @entity1 . In conclusion, we want to put some emphasis on the fact that, @entity3794 which is a late complication of radiotherapy at @entity5 , and the scar of @entity378 could be associated with @entity7167 and @entity540 expressions.
